Credit Suisse Reaffirms Their Buy Rating on Danaher Corp

By Austin Angelo

In a report issued on May 22, Erin Wright from Credit Suisse reiterated a Buy rating on Danaher Corp (NYSE: DHR), with a price target of $93. The company’s shares closed yesterday at $83.95.

According to, Wright is a 4-star analyst with an average return of 9.1% and a 63.8% success rate. Wright covers the Healthcare sector, focusing on stocks such as Quintiles Transnational, Quest Diagnostics Inc, and Phibro Animal Health.

Currently, the analyst consensus on Danaher Corp is Strong Buy and the average price target is $92, representing a 9.6% upside.

In a report issued on May 16, Jefferies also reiterated a Buy rating on the stock with a $95 price target.

The company has a one year high of $88.01 and a one year low of $73.40. Currently, Danaher Corp has an average volume of 2.62M.

Based on the recent corporate insider activity of 70 insiders, corporate insider sentiment is neutral on the stock. Last month, William Daniel, the EVP of DHR sold 17,444 shares for a total of $1,448,899.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Danaher Corp. operates as a medical company, which designs, manufactures, and markets healthcare, environmental, and industrial equipment. It operates through the following segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research and clinical tools that scientists use to study cells and cell components in order to understand the causes of diseases; identify new therapies; and test new drugs and vaccines. The Diagnostics segment comprises of analytical instruments, reagents, consumables, software, and services that hospitals, physician’s offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Dental segment develops products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums, and supporting bones; as well as provide dental consumables, equipment, and services. The Environmental & Applied Solution segment engages in the development and manufacture of equipment, consumables, and software for various printing, marking, coding, design, and color management applications on consumer and industrial products. The company was founded by Steven M. Rales and Mitchell P. Rales in 1969 and is headquartered in Washington, DC.